IDNA.US iShares Genomics Immunology and Healthcare ETF
- Total assets
- 354M
- Expense ratio
- 0.47%
- Dividend yield
- 0.66%
- 1-year return
- +69.51%
- Holdings
- 47
- Since
- 2019
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does IDNA.US invest in?
- Mostly US stocks (70.1%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (72.4%)
- Top 3 holdings: 24.1% of the fund
Asset allocation
- US stocks 70.1%
- Non-US stocks 31.8%
- Cash 0.2%
Top holdings
- Moderna Inc 13.58%
- Genmab A/S 5.98%
- Twist Bioscience Corp 4.58%
- Regeneron Pharmaceuticals Inc 4.30%
- Bayer AG NA 4.20%
iShares Genomics Immunology and Healthcare ETF performance
Sharpe ratio 1.25- This year
- +65.51%
- 1 year
- +69.51%
- 3 years
- +33.45%
- 5 years
- -1.36%
Volatility 29.2% over 1 year and 23.9% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
IDNA.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, …
Full fund profileiShares Genomics Immunology and Healthcare ETF top holdings
51.4% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Moderna Inc MRNA.US | Healthcare | United States | 13.58% |
| Genmab A/S GMAB.CO | Healthcare | Denmark | 5.98% |
| Twist Bioscience Corp TWST.US | Healthcare | United States | 4.58% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 4.30% |
| Bayer AG NA BAYN.XETRA | Healthcare | Germany | 4.20% |
| Takeda Pharmaceutical Co. Ltd. 4502.TSE | Healthcare | Japan | 4.10% |
| Exelixis Inc EXEL.US | Healthcare | United States | 3.88% |
| Merck & Company Inc MRK.US | Healthcare | United States | 3.66% |
| Incyte Corporation INCY.US | Healthcare | United States | 3.57% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 3.49% |
The 10 largest of 47 holdings.
IDNA.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
IDNA.US regional exposure
- North America72.4%
- Europe Developed21.6%
- Japan5.3%
- United Kingdom2.6%
- Asia Emerging1.5%
- Asia Developed0.2%
Share of the stocks in the fund.
Company size
Average market cap 22.8B- Mega cap12.4%
- Big cap21.7%
- Medium cap33.1%
- Small cap12.3%
- Micro cap18.1%
iShares Genomics Immunology and Healthcare ETF fund profile
- Fund name
- iShares Genomics Immunology and Healthcare ETF
- Ticker
- IDNA.US
- Exchange
- USA Stocks
- Issuer
- iShares
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Jun 11, 2019
- Trading currency
- USD
- Expense ratio
- 0.47%
- Annual turnover
- 0.4%
About iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.